Unigene Laboratories Explained

Unigene Laboratories
Type:Public
Industry:Biotechnology
Fate:Bankrupt
Hq Location City:New Jersey
Hq Location Country:United States
Products:Research and development of peptides for medical purposes
Num Employees:53
Num Employees Year:2020

Unigene Laboratories was an American biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey.[1] [2]

The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.[3] [4]

Unigene filed for Chapter 7 bankruptcy on July 2, 2013 in the United States Bankruptcy Court of the District of New Jersey. The Chapter 7 case is being administered under case No. 13-24696.

See also

Notes and References

  1. Web site: Unigene Laboratories Overview . Pitchbook . February 21, 2025 .
  2. News: Unigene Drops a Third of Its Staff and Restructures to Achieve 2010 Savings of $9–10M . December 9, 2009 . Genetic Engineering & Biotechnology News .
  3. News: Unigene Divests Site-Directed Bone Growth Patents to Kieran Murphy . September 21, 2011 . Genetic Engineering & Biotechnology News .
  4. News: GlaxoSmithKline to pay $420 Million for drug rights . April 16, 2002 . New York Times .